Share on StockTwits

Research analysts at Gabelli started coverage on shares of Durata Therapeutics (NASDAQ:DRTX) in a report released on Friday. The firm set a “hold” rating on the stock.

Other equities research analysts have also recently issued reports about the stock. Analysts at JMP Securities reiterated an “outperform” rating on shares of Durata Therapeutics in a research note on Thursday. They now have a $22.00 price target on the stock, up previously from $19.00. Separately, analysts at Roth Capital raised their price target on shares of Durata Therapeutics from $21.00 to $24.00 in a research note on Tuesday, May 27th. They now have a “buy” rating on the stock. Finally, analysts at RBC Capital raised their price target on shares of Durata Therapeutics from $19.00 to $23.00 in a research note on Tuesday, May 27th. They now have an “outperform” rating on the stock. Three analysts have rated the stock with a hold rating and seven have issued a buy rating to the stock. The stock currently has a consensus rating of “Buy” and a consensus price target of $19.88.

Shares of Durata Therapeutics (NASDAQ:DRTX) opened at 16.73 on Friday. Durata Therapeutics has a 1-year low of $6.70 and a 1-year high of $17.20. The stock’s 50-day moving average is $15.55 and its 200-day moving average is $13.55. The company’s market cap is $445.7 million.

Durata Therapeutics (NASDAQ:DRTX) last announced its earnings results on Thursday, May 8th. The company reported ($0.62) earnings per share for the quarter, beating the analysts’ consensus estimate of ($0.64) by $0.02. On average, analysts predict that Durata Therapeutics will post $-2.39 earnings per share for the current fiscal year.

In other Durata Therapeutics news, CEO Paul R. Edick bought 3,000 shares of the stock in a transaction that occurred on Thursday, June 12th. The shares were purchased at an average price of $15.23 per share, for a total transaction of $45,690.00. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link.

Durata Therapeutics, Inc is a pharmaceutical company focused on the development and commercialization of therapeutics for patients with infectious diseases and acute illnesses.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.